OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. (OKUR): 5 pipeline candidates · ~45 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
44.9 months
D/E 0.08
Lead: Phase 1
5 candidates
N/A
0 buys · 4 sells (180d)
A transparent, data-derived signal for OnKure Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$171.3M
Cash
$192.1M
Quarterly Burn
$12.9M
Runway
44.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| atirmociclib | Phase 1 |
| mavodelpar | Preclinical |
| oki-219 | Phase 1 |
| pan-mutant pi3kα inhibitor | Preclinical |
| pi3kα inhibitor | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$82.4M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 3,998,333 | $16.6M |
| acorn capital advisors, llc | 2,839,674 | $11.8M |
| adar1 capital management, llc | 2,434,941 | $10.1M |
| prosight management, lp | 2,154,381 | $8.9M |
| bvf inc/il | 1,978,972 | $8.2M |
| adage capital partners gp, l.l.c. | 1,204,819 | $5.0M |
| vanguard capital management llc | 1,164,954 | $4.8M |
| sio capital management, llc | 1,078,965 | $4.5M |
| nea management company, llc | 478,548 | $2.0M |
| rosalind advisors, inc. | 443,763 | $1.8M |
Showing top 10 of 46 institutional holders of OnKure Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in OnKure Therapeutics, Inc.'s pipeline?
OnKure Therapeutics, Inc. (OKUR) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OnKure Therapeutics, Inc.'s lead drug candidate?
OnKure Therapeutics, Inc.'s most advanced tracked candidate is atirmociclib (Phase 1) for Advanced Cancer.
What is OnKure Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OnKure Therapeutics, Inc. has approximately 44.9 months of cash runway.
What is OnKure Therapeutics, Inc.'s market capitalization?
OnKure Therapeutics, Inc.'s market capitalization is approximately $171.3M.
Who is the CEO of OnKure Therapeutics, Inc.?
Dr. Nicholas A. Saccomano Ph.D. is the chief executive officer of OnKure Therapeutics, Inc. (OKUR).
Get the full picture on OnKure Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.